Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liquid Alpha₁-PI vs Prolastin-C in AATD
NCT02282527Phase 3Completed
- Sponsor
- Grifols
- Start
- Oct 2014
- Primary completion
- Jan 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alpha1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD) (2 arms), sponsored by Grifols. Primary endpoint: Area Under the Curve (0-7 Days) Based on Antigenic Content. Started Oct 2014; status: completed.
02
Drugs
alpha1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT02282527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02282527.